Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer

• Type: Article in International Scientific Journal
• Date: 2014

Authors

Almeida, D (Author) Other; Gerhard, R (Author) Other; Leitao, D (Author) Other; Davilla, C (Author) Other; Damasceno, M (Author) Other; Fernando Schmitt (Author) FMUP

Journal

Title: Pathology Research and Practice

Vol. 210

Pages: 675-679

ISSN: 0344-0338

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 14 Citations

Scopus - 18 Citations

Other information

Authenticus ID: P-009-WPM

DOI: 10.1016/j.prp.2014.06.017

Abstract (EN): Amplification or deletion of the topoisomerase Hoe (TOP2A) gene in breast cancer has been related with responsiveness to anthracyclines-based chemotherapy. The purpose of this study was to evaluate the predictive value of TOP2A gene for the efficacy of neo-adjuvant anthracycline in a population with locally advanced breast cancer. Sixty-two patients were included, and the status of TOP2A gene was determined by in situ hybridization method. Treatment efficacy was determined by clinical and pathological response and overall survival. TOP2A gene alterations were found in 22.6% (21.0% of cases with amplification and 1.6% with deletion), and these tumors were biologically more aggressive, with higher nuclear grade, more frequently with HER2 amplification and inflammatory type. Also in these tumors response to chemotherapy appeared to be increased. There was a higher clinical and pathological response rate (complete pathological response of 21.4% vs. 8.3%), a trend toward longer progression-free survival (82.51 vs. 63.12 months) and a trend to increased overall survival (92.08 months; 95% CI 82.81-101.35 vs. 73.40 months; 95% Cl 63.44-83.36; p=0.113). These results corroborate that the TOP2A gene alterations may play an important role in determining anthracycline sensitivity in breast cancer.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 5